Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (371-380 of 692) with videos related to

Pageof 70
Sort By:
BJU International|July 24, 2009
Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic diseaseMichael J Donovan, Iman Osman, Faisal M Khan, et al.
Plos One|July 25, 2020
Current patterns of primary care provider practices for the treatment of post-traumatic headache in active duty military settingsRosemay A Remigio-Baker, Seth Kiser, Hamid Ferdosi, et al.
The Journal of Urology|March 1, 1992
The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary GroupT A Splinter, H I Scher, L Denis, et al.
JAMA Oncology|September 27, 2019
Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical TrialAmylou C Dueck, Howard I Scher, Antonia V Bennett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2005
Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancerMichael J Zelefsky, Leah Ben-Porat, Howard I Scher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2008
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancerMatthew D Galsky, Mario Eisenberger, Sandra Moore-Cooper, et al.
Journal of Neuro-Oncology|November 20, 2008
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)Teri N Kreisl, Andrew B Lassman, Paul S Mischel, et al.
The Journal of Headache and Pain|October 7, 2025
Prevalence of migraine in IcelandLarus S Gudmundsson, Sunna D Arnardottir, Dawn C Buse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2010
Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancerGustavo S P Meirelles, Heiko Schöder, Gregory C Ravizzini, et al.
Cancer|October 30, 2003
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinomaDavid B Solit, Michael Morris, Susan Slovin, et al.
Pageof 70

Showing results (371-380 of 692) with videos related to

Sort By:
Pageof 70
BJU International|July 24, 2009
Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic diseaseMichael J Donovan, Iman Osman, Faisal M Khan, et al.
Plos One|July 25, 2020
Current patterns of primary care provider practices for the treatment of post-traumatic headache in active duty military settingsRosemay A Remigio-Baker, Seth Kiser, Hamid Ferdosi, et al.
The Journal of Urology|March 1, 1992
The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary GroupT A Splinter, H I Scher, L Denis, et al.
JAMA Oncology|September 27, 2019
Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical TrialAmylou C Dueck, Howard I Scher, Antonia V Bennett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2005
Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancerMichael J Zelefsky, Leah Ben-Porat, Howard I Scher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2008
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancerMatthew D Galsky, Mario Eisenberger, Sandra Moore-Cooper, et al.
Journal of Neuro-Oncology|November 20, 2008
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)Teri N Kreisl, Andrew B Lassman, Paul S Mischel, et al.
The Journal of Headache and Pain|October 7, 2025
Prevalence of migraine in IcelandLarus S Gudmundsson, Sunna D Arnardottir, Dawn C Buse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2010
Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancerGustavo S P Meirelles, Heiko Schöder, Gregory C Ravizzini, et al.
Cancer|October 30, 2003
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinomaDavid B Solit, Michael Morris, Susan Slovin, et al.
Pageof 70